Neumora Therapeutics is trading at $0.41, down 5.58%; no confirmed company announcement explains the October 13 decline. - A report said Wall Street Zen lowered its rating to Strong Sell, but did not establish that the downgrade caused the move. - The supplied sector context shows biotech down 2.01%, which may be contributing but does not fully explain the larger stock decline. - The premarket gain mentioned in earlier coverage has reversed; the cause remains unclear.